The FDA has granted Sun Pharmaceutical Industries final approval for its lansoprazole delayed-release capsules in 15 mg and 30 mg strengths to address active duodenal ulcers. The drug is a generic equivalent of Takeda Pharmaceutical's Prevacid.
Dr. Reddy's Laboratories has obtained FDA approval to market delayed-release lansoprazole capsules, a copy of Takeda Pharmaceutical's ulcer drug Prevacid. The generic-drug maker is launching the product in 15- and 30-milligram strengths.
Legislation in the House calls for HHS to test the viability of health care innovation zones that bring together academic medical centers and health care facilities to improve patient outcomes and slow the growth of health care costs. The bill calls for payments to providers to be based on quality and outcomes, rather than units of service.
The Crohn's and Colitis Foundation of Canada has begun the Crohn's and Colitis Declaration to help lead a discussion about the difficulties people with IBD face every day that can affect quality of life. The campaign aims to improve education and reduce the stigma of the diseases.
Salix Pharmaceuticals Ltd. on Monday announced it submitted a new drug application for once-a-day dosing of granulated mesalamine to prevent the recurrence of ulcerative colitis. On the same day, Mylan announced that the FDA has approved its generic version of Colazal, Salix's key product for ulcerative colitis.